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Summary Background Elpamotide is an HLA-A*24:02-re-
stricted epitope peptide of vascular endothelial growth factor
receptor 2 (VEGFR-2) and induces cytotoxic T lymphocytes
(CTLs) against VEGFR-2/KDR. Given the high expression of
VEGFR-2 in b i l i a ry t rac t cancer, combina t ion
chemoimmunotherapy with elpamotide and gemcitabine holds
promise as a new therapy. Patients and Methods Patients with
unresectable advanced or recurrent biliary tract cancer were
included in this single-arm phase II trial, with the primary
endpoint of overall survival. Survival analysis was performed
in comparison with historical control data. The patients concur-
rently received gemcitabine once a week for 3 weeks (the fourth
week was skipped) and elpamotide once a week for 4 weeks.
Results Fifty-five patients were registered, of which 54 received
the regimen and were included in the full analysis set as well as
the safety analysis set. Median survival was 10.1 months, which
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was longer than the historical control, and the 1-year survival
rate was 44.4 %. Of these patients, injection site reactions were
observed in 64.8 %, in whommedian survival was significantly
longer (14.8 months) compared to those with no injection site
reactions (5.7 months). The response rate was 18.5 %, and all
who responded exhibited injection site reactions. Serious ad-
verse reactions were observed in five patients (9 %), and there
were no treatment-related deaths. Conclusion Gemcitabine and
elpamotide combination therapy was tolerable and had a mod-
erate antitumor effect. For future development of therapies, it
will be necessary to optimize the target population for which
therapeutic effects could be expected.
Keywords Biliary tract cancer . Immunotherapy . Cancer
vaccines . Phase II clinical trial . VEGFR2
Introduction
In Japan, the incidence of biliary tract cancer (BTC) was
ranked the sixth leading cause of cancer death in 2012. Al-
though BTC is rare in Europe and America, it is highly
prevalent in Japan, Chile, and East Asia [1, 2], presenting a
serious health concern. The only hope for a complete cure is
early-stage surgical resection. However, many BTC cases are
unresectable due to locally advanced or distant metastasis.
Moreover, recurrence after curative resection is not rare.
Therefore, effective pharmacotherapies must be developed.
Vascular endothelial growth factor (VEGF)-A and its recep-
tor, VEGF receptor (VEGFR), is highly expressed in many
tumors including BTC [3]. VEGFR-2/KDR strongly promotes
tumor angiogenesis, and active immunization against VEGFR-
2/KDR has been reported to inhibit tumor growth and metas-
tasis [4]. Thus, VEGFR-2/KDR holds hope as a target for
tumor immunotherapy. Elpamotide, an HLA-A*24:02-restrict-
ed epitope peptide derived from VEGFR-2/KDR (KDR169),
induces cytotoxic T lymphocytes (CTLs) that specifically rec-
ognize VEGFR-2/KDR169. These CTLs target tumor vascular
endothelial cells that express KDR169-presenting HLA mole-
cules, i.e., VEGFR-2/KDR expressing cells.
In this study, we assessed the efficacy and safety of com-
bination immunotherapy with gemcitabine (Gem) and
elpamotide in patients with BTC.
Methods
Study design
This multicenter, open-labeled, single-arm, phase II trial,
which recruited patients via central registration, was conduct-
ed in accordance with the Declaration of Helsinki and the
Standards for the Implementation of Clinical Trials on
Pharmaceutical Products. The primary endpoint was overall
survival, and secondary endpoints included progression-free
survival and tumor regression. Sixteen facilities participated in
this trial. This study was registeredwith UMIN, Clinical Trials
Registry before the enrollment of the first subject (Registra-
tion number: UMIN000002500). Inclusion criteria of this trail
were shown in Table 1.
Study treatment
One course of elpamotide (4 weeks) consisted of a single
weekly subcutaneous injection (2.0 mg/mL/body) on day 1,
day 8, day 15, and day 22. One course of Gem (4 weeks)
consisted of a single weekly mediation (1000 mg/m2/30 min)
on day 1, day 8, and day 15 (day 22 was skipped). Criteria for
discontinuation were shown in Table 1.
Efficacy and safety
Restaging CT was performed every 6 weeks and evaluated
according to RECIST criteria version 1.1. The final tumor
regression effect was determined by consensus of the image
evaluation committee. Overall survival was defined as time
Table 1 Criteria of this trial
Inclusion criteria
a) pathologically diagnosed adenocarcinoma or adenosquamous
carcinoma with bile duct origin (extrahepatic bile duct, intrahepatic
bile duct, gallbladder, or vater papilla)
b) unresectable or recurrent disease
c) HLA-A*24:02 positive
d) aged ≥20 years and <75 years
e) ECOG performance status of 0 or 1
f) expected to live for ≥3 months
g) adequate organ function meeting the following criteria:
white blood cell count ≥3500/mm3 and ≤12,000/mm3, neutrophil count
≥2000/mm3, hemoglobin ≥9.0 g/dL, platelet count ≥100,000/mm3,
total bilirubin ≤2.0 mg/dL, aspartate aminotransferase ≤150 IU/L,
alanine aminotransferase ≤150 IU/L, and serum creatinine ≤1.5 mg/
dL;
h) no previous history of chemotherapy, radiotherapy, or
immunotherapy for BTC
(eligible if adjuvant therapy with S-1 was performed ≥6 months before
registration)
i) if underwent laparotomy, it was performed ≥2 weeks before
registration
j) provision of written informed consent.
Criteria for discontinuation
a) when the primary disease observably worsened
b) when dose reduction of Gem was required for more than two stages
c) when adverse events made continuation difficult
d) when treatment was postponed for more than 28 days
e) when 1.5 years had passed from registration
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from the day of registration to the day of death from any cause
or 1.5 years afterwards. Progression-free survival was counted
from the day of registration to the day of progressive disease by
clinical evaluation or imaging diagnosis, whichever was earlier.
Adverse events were evaluated at each hospital visit and
graded according to the Common Toxicity Criteria version 3
(CTCAE v3). Adverse events which could not be ruled out as
being related to the trial therapy were reported as adverse drug
reactions (ADRs). For each adverse event, we documented the
worst grade for each patient, and confirmed the incidence of
each by grade.
Exploratory assessment
Induction of VEGFR-2-specific CTLs and serum concentra-
tions of VEGFR-2 were analyzed only in subjects who pro-
vided specific consent to receive these assessments at some of
the participating medical institutions.
The induction of VEGFR-2-specific CTLs was evaluated
by an enzyme-linked immunospot assay. CTL positivity was
defined as when the calculated value (average spot number in
the peptide pulse group - average spot number in the negative
control group/average spot number in the peptide pulse group
× 100) by timewas greater than that of day 1, and further when
the average spot number in the peptide pulse group was
greater than the average spot number and standard deviation
range in the negative control group.
Serum concentrations of VEGFR-2 were measured before
drug administration on day 1, day 8, and day 29, using
Quantikine® Human Soluble VEGFR-2 Immunoassay
(R&D Systems, Inc).
Statistical analysis
Overall survival, 1-year survival and progression-free survival
were estimated with the Kaplan-Meier method. To assess differ-
ences in overall survival between the elpamotide and historical
control groups [5, 6], log-rank tests and the Harrington-Fleming,
in which time is weighted and was used in anticipation that the
effects of the vaccine would present with time, were used.
Calculation of sample size was based on an additional
treatment effect of 15 % in the elpamotide group compared
with the 1-year survival rate in the historical control group,
which was derived from previous reports [5, 6]. The null
hypothesis was “no extension of 1-year survival” to achieve a
one-sided type I error of <10 % and a power of >80 %. We
estimated that the 1-year survival rate of the historical control
group based on patients with BTC was 15–30 %, and expected
elpamotide to add a treatment effect of 15 %. When the histor-
ical control group was set at 200 patients, the sample size
needed for the elpamotide group was calculated to be 45–60
patients. Accordingly, we aimed to select a total of 50 patients.
Serum concentrations of VEGFR-2 were analyzed by post-
hoc test. All statistical analyses were conducted with SAS
software, version 9.1.3 (SAS Institute).
Results
Patient characteristics
Of the 55 patients registered from October 2009 to June 2011,
54 who underwent the trial therapy were included in the full
analysis set and safety analysis set. Patient characteristics are
summarized in Table 2. Compared to the historical control
group, the present trial had higher proportions of patients
without gallbladder cancer (66.7 % vs. 45–50.7 %) and those
having a performance status of 0 (90.7 % vs. 60 %).
Survival and response rate
Fourteen patients (25.9 %) survived ≥1.5 years, and two
completed the 1.5-year trial therapy. The median number of
courses of study treatment was 4.5 (range: 1–20), and the dose
intensity of elpamotide and Gem was 90.0 and 82.7 %,
Table 2 Patient characteristics (N _54)*








Intrahepatic bile duct 20 37
Gallbladder 18 33.3
Extrahepatic bile duct 13 24.1
Ampulla of vater 3 5.6
Extent of disease
Metastatic 34 63





≥18 % 45 83.3




Clinical characteristics of the 54 patients who received elpamotide+GEM
PS (ECOG) Performance status (Eastern Cooperative Oncology Group)
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respectively. Main reasons for discontinuation were exacerba-
tion of primary disease (34 cases) and adverse event-related
reasons (6 cases).
Median survival was 10.1 months (95 % confidence inter-
val (CI): 8.0–14.0 months), which was longer than that of the
historical control (7.6months) (P=0.079; Harrington-Fleming
method; P=0.043, log-rank test; Fig. 1). One-year survival
rate was 44.4 %, and median progression-free survival was
4.5 months (95 % CI: 2.8–7.1 months).
Median overall survival by site of origin was as follows:
intrahepatic bile duct (11.6 months), extrahepatic bile duct
(18.3 months), gallbladder (8.4 months), and vater papilla
(9.8 months). These were superior to the 8.7, 10.1, 6.5, and
9.3 months, respectively, in the historical control.
None of the patients achieved complete response, while 10
achieved partial response, with the imaging response rate of
18.5 %. Stable disease was maintained for ≥6 months in 8 of
28 patients (14.8 %).
Toxicity
Major hematologic ADRs included decreased white blood cell
counts (75.9 %), decreased platelet counts (72.2 %), and
decreased neutrophil counts (64.8 %). Major non-
hematologic ADRs included injection site reaction (68.5 %),
induration and erythema (64.8 and 27.8 %), nausea (51.9 %),
and decreased appetite and malaise (37.0 %). Severe adverse
effects were observed in five patients as follows:
pneumocystis pneumonia, loss of appetite, thrombotic micro-
angiopathy, interstitial lung disease, and fever. ADRs of grade
3 or higher are summarized in Table 3. There were no
treatment-related deaths.
Subgroup analysis
Among 37 patients who developed injection site reactions
(ulcer, induration, or erythema), tumor regression was ob-
served in 10 (27 %) during the study period. Moreover, the
median overall survival of the 37 patients was significantly
longer (14.8 months) compared to that of the remaining 17
who developed no injection site reactions (5.7months; Table 4
and Fig. 2).
Table 3 Adverse drug reactions
Adverse drug reactions Grade 3 Grade 4
N % N %
Hematological
Decreased neutrophil count 16 29.6 3 5.6
Decreased lymphocyte count 9 16.7 0 0.0
Decreased white blood cell count 5 9.3 0 0.0
Decreased platelet count 4 7.4 1 1.9
Anemia 2 3.7 0 0.0
Non-hematological
Pneumocystis jiroveci pneumonia 1 1.9 0 0.0
Thrombotic microangiopathy 1 1.9 0 0.0
Decreased appetite 1 1.9 0 0.0
Interstitial lung disease 1 1.9 0 0.0
Elevated alanine aminotransferase level 1 1.9 0 0.0
Elevated aspartate aminotransferase level 1 1.9 0 0.0
Elevated blood glucose level 1 1.9 0 0.0
Elevated gamma-glutamyltransferase level 1 1.9 0 0.0
Elevated hepatic enzyme level 1 1.9 0 0.0
Fig. 1 Overall survival
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Exploratory analysis
The induction of VEGFR2-specific CTLs was assessed in
nine patients; six were positive (66.7 %). There was no clear
association between CTL positivity with treatment survival,
response rate, or ADRs.
Serum concentrations of VEGFR-2 were evaluated in 43
patients, and found to be significantly increased from baseline
(day 1) to day 8 (P=0.015), and significantly decreased from
day 8 to day 29 (P=0.010); there was no significant difference
from baseline to day 29. Response rate in the 31 patients
(72 %) with an elevated serum VEGFR-2 concentration at
day 8 was 19 %, and median survival was 13.3 months. There
was no apparent association between serum VEGFR-2 con-
centration and efficacy or ADRs.
Discussion
Tumor immunotherapy has recently gained much atten-
tion, and there are currently more than 100 clinical
studies in progress around the world. As a results, some
immunotherapeutic drugs already approved [7, 8], and
such approval reflects the findings that immunotherapy
activates the immune response in cancer patients and is
clinically effective.
The present trial was planned and conducted before
Gem plus cisplatin therapy became the standard chemo-
therapy for BTC based on results of the ABC-02 [9]
and BT-22 [10] trials. The reliable reference data at the
time of planning this trial were only the retrospective
data from two studies [5, 6]. Based on results from
those studies, we set the threshold 1-year survival rate
at 15–30 %, and expected to add a 15 % treatment
effect. The result was a 44.4 % 1-year survival rate,
which was in line with this prediction. However, the
proportion of good performance status cases and of
those without gallbladder cancer were high in this trial.
Thus, in the comparison with the historical control,
improved survival may have been related to patient
background, rather than the vaccine’s additive effects.
Median survival with the standard Gem plus cisplatin
Fig. 2 Overall survival with or
without injection site reactions
Table 4 Relationship between
the efficacy and injection site
reactions
CI confidence interval, ISR
injection site reaction
With ISR (n=37) Without ISR (n=17)
N (%) N (%) P-value
Response
Complete response (CR) 0 (0.0) 0 (0.0)
Partial response (PR) 10 (27.0) 0 (0.0)
Stable disease (SD) 20 (54.1) 8 (47.1)
Progressive disease (PD) 7 (18.9) 7 (41.2)
Not evaluable (NE) 0 (0.0) 2 (11.8)
Overall survival
Median survival (95 % CI) 14.8 months (9.8, 18.4) 5.7 months (4.6, 8.6) 0.002 (H-F),
<0.001 (log-rank)
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therapy in the ABC-02 and BT22 trials was 11.7 and
11.2 months, respectively. Based on the median survival of
10.1 months in the present trial, single-agent Gem chemother-
apy clearly lacks power as a platform for additive effects over
elpamotide.
Survival curves for subgroups of patients who did and did
not exhibit injection site reactions differed substantially. The
fact that those who exhibited injection site reactions showed
better long-term results suggests that it can be used as an
indicator for early determination of those likely to benefit
from therapy. This phenomenon was also observed in the
Gem ± elpamotide trial (PEGASUS-PC Study), which
targeted advanced pancreatic cancer patients, and although
primitive, it may serve as a highly reliable indicator.
In conclusion, combined immunotherapy with Gem and
elpamotide was well-tolerated and showed moderate antitu-
mor effects. For future development of therapies, it will be
necessary to optimize the target population for which thera-
peutic effects could be expected.
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